Figure 1

Amelioration of psoriasis by treatment of mice xenotransplanted with psoriatic skin with systemically administered p40-targeting antibodies. (a) Schematic schedule of treatment with p40-targeting antibodies (Ustekinumab). Psoriatic skin grafts were xenotransplanted onto the back of SCID mice and allowed to heal for ten days. The mice were then treated by weekly intraperitoneal injection of p40-targeting antibodies or negative control. The mice were sacrificed after three weeks of treatment. (b) Semiquantitative clinical psoriasis scores were given twice weekly for the three-week treatment duration to mice treated with the negative control (open circles, n = 11) or p40-targeting antibodies (open squares, n = 4). Injections were performed at day 0, 7, and 14. All data points are presented as mean ± SEM. *p = 0.003. (c) At treatment endpoint, mice were sacrificed and biopsies from the skin grafts were fixed, paraffin-embedded, H&E-stained, and epidermal thickness was measured in each graft. All data points are presented as mean + SEM.